S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
U.S. Loses to China in Shocking WAR GAMES (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Laser breakthrough could send stock soaring 2,467% (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
U.S. Loses to China in Shocking WAR GAMES (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Laser breakthrough could send stock soaring 2,467% (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
U.S. Loses to China in Shocking WAR GAMES (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Laser breakthrough could send stock soaring 2,467% (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
U.S. Loses to China in Shocking WAR GAMES (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Laser breakthrough could send stock soaring 2,467% (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
NASDAQ:APLM

Apollomics (APLM) Stock Forecast, Price & News

$3.76
+0.16 (+4.44%)
(As of 09/22/2023 ET)
Compare
Today's Range
$3.48
$3.90
50-Day Range
$3.60
$5.82
52-Week Range
$3.48
$49.00
Volume
27,208 shs
Average Volume
7,516 shs
Market Capitalization
$326.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

APLM stock logo

About Apollomics (NASDAQ:APLM) Stock

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

APLM Price History

APLM Stock News Headlines

Apollomics, Inc. (NASDAQ:APLM) Short Interest Update
APLM - Apollomics, Inc.
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Apollomics (NASDAQ: APLM)
See More Headlines
Receive APLM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter.

APLM Company Calendar

Today
9/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLM
Fax
N/A
Employees
43
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.45 million
Book Value
($33.37) per share

Miscellaneous

Free Float
N/A
Market Cap
$326.37 million
Optionable
Not Optionable
Beta
0.94

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Guo-Liang Yu Ph.D. (Age 60)
    Co-Founder, CEO & Exec. Chairman
  • Dr. Sanjeev Redkar MBA (Age 54)
    Ph.D., Co-Founder, Pres, CFO & Exec. Director
  • Dr. Lijuan Jane Wang Ph.D. (Age 59)
    Chief Scientific Officer & GM of China
  • Ms. Brianna MacDonald J.D.
    Sr. VP & Gen. Counsel
  • Dr. Kin-Hung Yu M.D. (Age 61)
    Chief Medical Officer
  • Dr. Chinglin Lai Ph.D.
    Sr. VP of Biostatistics & Data Management













APLM Stock - Frequently Asked Questions

Should I buy or sell Apollomics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apollomics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APLM shares.
View APLM analyst ratings
or view top-rated stocks.

How have APLM shares performed in 2023?

Apollomics' stock was trading at $24.20 on January 1st, 2023. Since then, APLM stock has decreased by 84.5% and is now trading at $3.76.
View the best growth stocks for 2023 here
.

Are investors shorting Apollomics?

Apollomics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 4,100 shares, an increase of 57.7% from the August 15th total of 2,600 shares. Based on an average daily volume of 21,300 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's stock are sold short.
View Apollomics' Short Interest
.

What ETF holds Apollomics' stock ?

Range Cancer Therapeutics ETF holds 26,270 shares of APLM stock, representing 1.45% of its portfolio.

What is Apollomics' stock symbol?

Apollomics trades on the NASDAQ under the ticker symbol "APLM."

Who are Apollomics' major shareholders?

Apollomics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.03%), Levin Capital Strategies L.P. (0.01%) and BlackRock Inc. (0.01%).

How do I buy shares of Apollomics?

Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollomics' stock price today?

One share of APLM stock can currently be purchased for approximately $3.76.

How much money does Apollomics make?

Apollomics (NASDAQ:APLM) has a market capitalization of $326.37 million and generates $1.45 million in revenue each year.

How can I contact Apollomics?

Apollomics' mailing address is 5/F-4 NO. 89 SONGREN ROAD XINYI DISTRICT, TAIPEI CITY F5, 11073. The official website for the company is www.apollomicsinc.com. The company can be reached via phone at 886-2-7713-7952.

This page (NASDAQ:APLM) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -